Hilda M Parker
Nurse Practitioner · Miami
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 26 years
- Graduated 2000
Offices
1 location · Public Health Trust of Miami Dade County Florida · 469 clinicians in this group
Hospitals listed: Jackson Memorial Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Hilda M Parker’s office at (305) 585-1111 to ask if they take your plan before you enroll.
California Medical Board record
Licence A21341 · Deceased
Licence status: Deceased · since 1964 · University of Southern California Keck School of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Jackson Health SystemMiami, FLAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Jackson Health System, which runs 3 hospitalsPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.3 (1.02 to 1.58), Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 218.24 (176.7 to 259.77) · 155 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.62 (3.71 to 7.53) · 2,070 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 16.87 (10.39 to 23.35) · 766 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.081, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.052, Oct 2024 – Sep 2025
See every measure and the patient survey for Jackson Health System
Behind the star rating — Deaths: 0 better, 3 the same, 4 worse of 7 measures. Safety: 3 better, 3 the same, 1 worse of 7 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.3 (1.02 to 1.58) | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 218.24 (176.7 to 259.77) · 155 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.62 (3.71 to 7.53) · 2,070 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 16.87 (10.39 to 23.35) · 766 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.052 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.7 (0 to 1.6) · 2,368 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11.4 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.1 · 1,088 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 9,348 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.37 (0.18 to 0.56) · 9,446 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.37) · 9,979 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.09 (0.55 to 3.63) · 719 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.52 to 3.07) · 2,080 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.83 (2.34 to 9.31) · 726 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.08 (0.67 to 3.49) · 643 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0.08 to 1.04) · 9,317 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 218 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.744 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.5 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 876 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.3 · 2,815 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 68.3 · 457 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.8 · 515 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 2,037 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.6 to 8.7) · 37 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (8.1 to 16.8) · 37 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 224 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 137 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 931 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.4 to 18.6) · 348 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 206 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,911 patients answered, 9% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 60% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$2,932
Medicare paid this office $2,932 for 34 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $2,806 | $88 |
Who their Medicare patients are
34 Original Medicare patients in 2024. Average age 74 · Women 53% · Health risk score 4.38. Sicker patients than 9 in 10 peers; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 74% · Heart failure 68% · Coronary heart disease 59% · Stroke 56% · Depression 53% · Chronic kidney disease 50% · Atrial fibrillation 50% · Dementia 50% · COPD 47%.
The office billed $9,304, Medicare allowed $3,938 and paid $2,932; for 39 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 34 | 39 | 74 | 4.38 | $9,304 | $2,932 |
| 2023 | 18 | 18 | 72 | 6.95 | $7,958 | $1,739 |
| 2017 | 36 | 45 | 57 | 4.60 | $8,914 | $2,475 |
| 2016 | 46 | 52 | 62 | 3.94 | $9,518 | $2,682 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,239 | $95 |
2017: 1 service
| Return visit (30+ min) | 33 | $1,966 | $50 |
2016: 1 service
| Return visit (30+ min) | 30 | $2,118 | $59 |
Medicaid work
$0 in 2022
Medicaid paid $0 for 19 billed services this clinician did in 2022, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 19 | $0 |
| 2022 | 19 | 1 | 19 | $0 |
Drugs they prescribed that Part D paid
$14,512
Pharmacies billed $14,512 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 226) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
220 generic and fewer than 11 brand-name prescriptions · $14,512 in drug cost · 23 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nifedipine Er | 13 | $424 | $33 |
| Rosuvastatin | 16 | $107 | $7 |
| Carvedilol | 31 | $84 | $3 |
| Omeprazole | 11 | $71 | $6 |
| Prednisone | 21 | $50 | $2 |
See all 6 drugs
| Nifedipine Er | 13 | $424 | $33 |
| Rosuvastatin | 16 | $107 | $7 |
| Carvedilol | 31 | $84 | $3 |
| Omeprazole | 11 | $71 | $6 |
| Prednisone | 21 | $50 | $2 |
| Sulfamethoxazole-Trimethoprim | 21 | $25 | $1 |
Year by year
| 2024 | 226 | 48 | 0% (0) | None | $14,512 |
| 2023 | 1,787 | 128 | None | 11% | $834,995 |
| 2022 | 1,472 | 108 | None | None | $314,842 |
| 2021 | 1,294 | 105 | None | None | $299,847 |
| 2020 | 613 | 89 | 0% (0) | None | $412,651 |
| 2019 | 15 | None | 0% (0) | None | $393 |
| 2018 | 13 | None | 0% (0) | None | $3,765 |
| 2017 | 66 | 26 | None | None | $32,292 |
| 2016 | 354 | 74 | None | 40% | $248,259 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 38 drugs
| Privigen | Immune globulin | 16 | $229,087 | $14,318 |
| Eliquis | None | 42 | $28,693 | $683 |
| Veltassa | None | 15 | $18,922 | $1,261 |
| Mycophenolic Acid | None | 32 | $15,561 | $486 |
| Valganciclovir | None | 27 | $13,003 | $482 |
| Tacrolimus | None | 59 | $12,843 | $218 |
| Retacrit | None | 11 | $10,477 | $952 |
| Januvia | None | 11 | $9,583 | $871 |
| Fludrocortisone Acetate | None | 158 | $7,244 | $46 |
| Sirolimus | None | 16 | $5,818 | $364 |
| Dapsone | None | 79 | $5,695 | $72 |
| Lamivudine Hbv | None | 12 | $5,075 | $423 |
| Nifedipine Er | None | 38 | $1,982 | $52 |
| Lactulose | None | 23 | $1,305 | $57 |
| Losartan | None | 65 | $1,189 | $18 |
| Rosuvastatin | None | 82 | $1,084 | $13 |
| Carvedilol | None | 127 | $985 | $8 |
| Prednisone | None | 141 | $720 | $5 |
| Gabapentin | None | 42 | $633 | $15 |
| Omeprazole | None | 43 | $632 | $15 |
| Pantoprazole | None | 46 | $574 | $12 |
| Famotidine | None | 49 | $571 | $12 |
| Atorvastatin | None | 50 | $539 | $11 |
| Metoclopramide | None | 48 | $494 | $10 |
| Potassium Chloride | None | 17 | $488 | $29 |
| Sulfamethoxazole-Trimethoprim | None | 73 | $459 | $6 |
| Fenofibrate | None | 12 | $445 | $37 |
| Hydralazine | None | 22 | $444 | $20 |
| Tamsulosin | None | 22 | $442 | $20 |
| Metoprolol | None | 34 | $359 | $11 |
| Rabeprazole | None | 13 | $306 | $24 |
| Levothyroxine | None | 14 | $212 | $15 |
| Methylprednisolone | None | 14 | $191 | $14 |
| Amlodipine Besylate | None | 11 | $138 | $13 |
| Alendronate | None | 18 | $129 | $7 |
| Furosemide | None | 13 | $120 | $9 |
| Clopidogrel | None | 11 | $97 | $9 |
| Calcitriol | None | 11 | $92 | $8 |
2022: 30 drugs
| Procrit | 14 | $57,872 | $4,134 |
| Tacrolimus | 56 | $16,511 | $295 |
| Valganciclovir | 20 | $14,412 | $721 |
| Mycophenolic Acid | 26 | $9,813 | $377 |
| Eliquis | 12 | $6,811 | $568 |
| Fludrocortisone Acetate | 119 | $4,523 | $38 |
| Rosuvastatin | 118 | $3,450 | $29 |
| Rabeprazole | 12 | $3,426 | $285 |
| Nifedipine Er | 39 | $2,384 | $61 |
| Dapsone | 22 | $1,650 | $75 |
| Omeprazole | 77 | $1,289 | $17 |
| Carvedilol | 77 | $1,272 | $17 |
| Losartan | 82 | $1,118 | $14 |
| Gabapentin | 48 | $1,016 | $21 |
| Nitrofurantoin | 11 | $862 | $78 |
| Tamsulosin | 41 | $652 | $16 |
| Prednisone | 101 | $640 | $6 |
| Hydralazine | 26 | $476 | $18 |
| Clopidogrel | 25 | $410 | $16 |
| Ondansetron | 17 | $406 | $24 |
| Metoclopramide | 36 | $362 | $10 |
| Pantoprazole | 24 | $356 | $15 |
| Atorvastatin | 31 | $335 | $11 |
| Sulfamethoxazole-Trimethoprim | 59 | $303 | $5 |
| Atenolol | 11 | $221 | $20 |
| Levothyroxine | 13 | $201 | $15 |
| Metoprolol | 25 | $194 | $8 |
| Furosemide | 13 | $191 | $15 |
| Amlodipine Besylate | 16 | $54 | $3 |
| Simvastatin | 13 | $32 | $2 |
2021: 34 drugs
| Octagam | Immune globulin | 11 | $130,670 | $11,879 |
| Procrit | None | 12 | $54,861 | $4,572 |
| Retacrit | None | 12 | $17,799 | $1,483 |
| Cinacalcet | None | 23 | $16,427 | $714 |
| Valganciclovir | None | 14 | $13,117 | $937 |
| Mycophenolic Acid | None | 26 | $11,527 | $443 |
| Tacrolimus | None | 36 | $7,357 | $204 |
| Rosuvastatin | None | 120 | $4,266 | $36 |
| Fludrocortisone Acetate | None | 133 | $3,897 | $29 |
| Nifedipine Er | None | 39 | $3,651 | $94 |
| Dapsone | None | 46 | $2,916 | $63 |
| Nitrofurantoin | None | 18 | $1,291 | $72 |
| Labetalol | None | 15 | $1,117 | $74 |
| Carvedilol | None | 85 | $896 | $11 |
| Ethambutol | None | 14 | $733 | $52 |
| Omeprazole | None | 44 | $502 | $11 |
| Prednisone | None | 76 | $459 | $6 |
| Losartan | None | 69 | $440 | $6 |
| Tamsulosin | None | 32 | $421 | $13 |
| Pantoprazole | None | 13 | $353 | $27 |
| Famotidine | None | 26 | $335 | $13 |
| Atorvastatin | None | 33 | $244 | $7 |
| Hydralazine | None | 17 | $226 | $13 |
| Ondansetron | None | 13 | $197 | $15 |
| Gabapentin | None | 23 | $169 | $7 |
| Metoprolol | None | 31 | $163 | $5 |
| Furosemide | None | 21 | $147 | $7 |
| Metoclopramide | None | 13 | $138 | $11 |
| Sulfamethoxazole-Trimethoprim | None | 31 | $122 | $4 |
| Alendronate | None | 11 | $76 | $7 |
| Clopidogrel | None | 15 | $57 | $4 |
| Cephalexin | None | 12 | $56 | $5 |
| Lisinopril | None | 20 | $33 | $2 |
| Metformin | None | 12 | $27 | $2 |
2020: 19 drugs
| Octagam | Immune globulin | 19 | $207,896 | $10,942 |
| Cinacalcet | None | 26 | $20,313 | $781 |
| Voriconazole | None | 15 | $6,999 | $467 |
| Mycophenolic Acid | None | 20 | $6,570 | $328 |
| Tacrolimus | None | 12 | $2,774 | $231 |
| Fludrocortisone Acetate | None | 62 | $1,807 | $29 |
| Nitrofurantoin | None | 12 | $783 | $65 |
| Rosuvastatin | None | 32 | $753 | $24 |
| Levofloxacin | None | 15 | $544 | $36 |
| Prednisone | None | 31 | $269 | $9 |
| Losartan | None | 34 | $235 | $7 |
| Tamsulosin | None | 14 | $228 | $16 |
| Carvedilol | None | 34 | $193 | $6 |
| Metoclopramide | None | 11 | $173 | $16 |
| Metoprolol | None | 17 | $112 | $7 |
| Hydralazine | None | 13 | $111 | $9 |
| Sulfamethoxazole-Trimethoprim | None | 21 | $74 | $4 |
| Famotidine | None | 11 | $71 | $6 |
| Lisinopril | None | 14 | $50 | $4 |
2017: 1 drug
| Ursodiol | 14 | $3,249 | $232 |
2016: 9 drugs
| Xifaxan | 26 | $48,641 | $1,871 |
| Baraclude | 44 | $30,408 | $691 |
| Entecavir | 38 | $21,913 | $577 |
| Viread | 21 | $20,964 | $998 |
| Ursodiol | 40 | $14,244 | $356 |
| Lactulose | 18 | $348 | $19 |
| Spironolactone | 28 | $246 | $9 |
| Prednisone | 14 | $167 | $12 |
| Furosemide | 23 | $96 | $4 |
Money from drug and device companies
$97 in 2025
| 2025 | 1 | 1 | None | $97 |
| 2023 | 2 | 2 | None | $145 |
| 2021 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $97 | 1 payment
|
See the published payment
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-22 | Lifevest | $97 |
See earlier years (2023, 2021)
2023: $145
| E.R. Squibb & Sons L.L.C. | Camzyos | $122 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $23 | 1 payment
|
2021: $125
| AstraZeneca Pharmaceuticals LP | Lokelma | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1699739482
- Licence
- CA 21341, FL APRN2718332, MI 4704394022, OR 201506150NP-PPCalifornia A21341: Deceased
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- FL 3036413-00
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X); Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 1801 Nw 9th Ave Bldg Suite500, Miami, FL, 33136
- NPI first listed
- 2006-04-17
- NPI last updated
- 2024-06-19
- NPI record certified
- 2024-06-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305